Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include creamer and chocolate systems, dairy replacers, powdered fats, nutritional beverage bases, beverages, juice and dairy bases, ice cream bases and variegates, cereals, grain based snacks, and cereal based ingredients. This segment also offers microencapsulation solutions; and human grade choline nutrients and mineral amino acid chelated products for wellness applications. Its Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The company's Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. It also sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company's Industrial Products segment provides choline chloride derivatives for hydraulic fracturing of shale natural gas wells; and methylamines, which are building blocks for the manufacture of choline products, as well as used in industrial applications. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was founded in 1967 and is headquartered in New Hampton, New York.
Industry, Sector and Symbol
Industry Chemicals & allied products
Sub-IndustrySpecialty Chemicals
SectorBasic Materials
Phone845-326-5600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$643.68 million
Profitability
Miscellaneous
Employees1,135
Next Earnings Date8/2/2019 (Estimated)
OptionableOptionable
Balchem (NASDAQ:BCPC) Frequently Asked Questions
What is Balchem's stock symbol?
Balchem trades on the NASDAQ under the ticker symbol "BCPC."
How often does Balchem pay dividends? What is the dividend yield for Balchem?
Balchem declared an annual dividend on Wednesday, December 12th. Shareholders of record on Wednesday, December 26th will be given a dividend of $0.47 per share on Friday, January 18th. This represents a yield of 0.59%. The ex-dividend date is Monday, December 24th. This is a boost from Balchem's previous annual dividend of $0.42. View Balchem's Dividend History.
How were Balchem's earnings last quarter?
Balchem Co. (NASDAQ:BCPC) released its earnings results on Friday, May, 3rd. The basic materials company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.69 by $0.04. The basic materials company had revenue of $157 million for the quarter, compared to the consensus estimate of $165.57 million. Balchem had a return on equity of 14.11% and a net margin of 12.20%. The business's quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.76 EPS. View Balchem's Earnings History.
When is Balchem's next earnings date?
What price target have analysts set for BCPC?
4 equities research analysts have issued 1 year price targets for Balchem's shares. Their predictions range from $100.00 to $127.00. On average, they expect Balchem's stock price to reach $112.3333 in the next year. This suggests a possible upside of 18.5% from the stock's current price. View Analyst Price Targets for Balchem.
What is the consensus analysts' recommendation for Balchem?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Balchem in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Balchem.
What are Wall Street analysts saying about Balchem stock?
Here are some recent quotes from research analysts about Balchem stock:
- 1. According to Zacks Investment Research, "Balchem Corporation provides state-of-the-art solutions and the finest quality products for a range of industries worldwide. Balchem Company consists of four business segments: Human Nutrition & Health; Animal Nutrition & Health; Specialty Products; and Industrial Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. The Industrial Products segment manufactures and supplies certain derivative products into industrial applications. " (5/8/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a comparable universe-derived EV-to-EBITDA multiple approach. EV-to-EBITDA multiple to our 2019 diluted EBITDA per share of $3.64, we derive a target of $110 per share. Risks include, but are not limited to: (1) slower-than-anticipated growth in Balchem’s base businesses; (2) a global fracking industry slowdown; (3) inability to launch new nutrition segment products; and (4) failure by Balchem’s partner Curemark to obtain approval for its autism drug candidate." (5/6/2019)
- 3. Pivotal Research analysts commented, "We are raising our adjusted EPS estimates to $3.05 for 2018 and $3.35 for 2019 ($2.95 and $3.20 previously). We continue to view the company as very attractive, but the shares remain fully-priced. We are boosting our price target to $95 from $85 based on 28.4x 2019 EPS; The shares trade today at 19.3x EV/EBITDA. FCF yield is only 3%. BCPC has done a superb job, we can only hope for a better entry point." (8/3/2018)
Has Balchem been receiving favorable news coverage?
News articles about BCPC stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Balchem earned a daily sentiment score of 1.9 on InfoTrie's scale. They also gave press coverage about the basic materials company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Balchem's key competitors?
Some companies that are related to Balchem include FMC (FMC), W. R. Grace & Co (GRA), Huntsman (HUN), Ashland Global (ASH), Ingevity (NGVT), Chemours (CC), Univar (UNVR), Olin (OLN), PQ Group (PQG), Innospec (IOSP), GCP Applied Technologies (GCP), KMG Chemicals (KMG), Nexeo Solutions (NXEO), Innophos (IPHS) and Hawkins (HWKN).
What other stocks do shareholders of Balchem own?
Who are Balchem's key executives?
Balchem's management team includes the folowing people:
- Mr. Theodore L. Harris, Chairman and Chief Exec. Officer (Age 54)
- Mr. William A. Backus CPA, Chief Accounting Officer (Age 53)
- Mr. Mark A. Stach, Gen. Counsel & Corp. Sec.
- Mr. David F. Ludwig, VP & Gen. Mang. of Industrial Products (Age 61)
- Mr. Carl Martin Bengtsson, Chief Financial Officer
Who are Balchem's major shareholders?
Balchem's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.43%), Wasatch Advisors Inc. (3.81%), Conestoga Capital Advisors LLC (2.48%), Dimensional Fund Advisors LP (2.32%), Northern Trust Corp (1.46%) and Macquarie Group Ltd. (1.28%). Company insiders that own Balchem stock include Daniel E Knutson and Edward Mcmillan. View Institutional Ownership Trends for Balchem.
Which major investors are selling Balchem stock?
BCPC stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Morgan Stanley, Pennsylvania Trust Co, BlackRock Inc., First Trust Advisors LP, PNC Financial Services Group Inc., Renaissance Technologies LLC and Eagle Asset Management Inc.. View Insider Buying and Selling for Balchem.
Which major investors are buying Balchem stock?
BCPC stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Ellis Investment Partners LLC, Ellis Investment Partners LLC, Man Group plc, Oxford Asset Management LLP, 361 Capital LLC, Geode Capital Management LLC and Tributary Capital Management LLC. View Insider Buying and Selling for Balchem.
How do I buy shares of Balchem?
Shares of BCPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Balchem's stock price today?
One share of BCPC stock can currently be purchased for approximately $94.83.
How big of a company is Balchem?
Balchem has a market capitalization of $3.07 billion and generates $643.68 million in revenue each year. The basic materials company earns $78.57 million in net income (profit) each year or $3.01 on an earnings per share basis. Balchem employs 1,135 workers across the globe.
What is Balchem's official website?
How can I contact Balchem?
Balchem's mailing address is 52 Sunrise Park Road, NEW HAMPTON NY, 10958. The basic materials company can be reached via phone at 845-326-5600 or via email at [email protected]
MarketBeat Community Rating for Balchem (NASDAQ BCPC)
MarketBeat's community ratings are surveys of what our community members think about Balchem and other stocks. Vote "Outperform" if you believe BCPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCPC will underperform the S&P 500 over the long term. You may vote once every thirty days.
